Back

Serum Trimethylamine N-Oxide levels and 16S rRNA gut microbiota profiling in patients with heart failure and preserved ejection fraction and healthy individuals

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Heart failure with preserved ejection fraction Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Oxana Drapkina

National Research Center for Preventive Medicine, Moscow (Russian Federation)

4 More presentations in this session

Presentation thumbnail
State of the Art - Diagnosis of heart failure with preserved ejection fraction: What's new?
Professor B. Pieske (Rostock, DE)
Slides Video
Presentation thumbnail
Metabolomic profile of patients with new onset heart failure; more microvascular dysfunction in patients with preserved ejection fraction compared to reduced ejection fraction - the PREFERS Study
Assistant Professor C. Hage (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Different impact of muscle, fat, and bone mass in heart failure with reduced and preserved ejection fraction
Doctor M. Konishi (Yokohama, JP)
Abstract Slides Video
Presentation thumbnail
Heart failure with preserved ejection fraction: how to further improve patient outcomes?
Professor M. Senni (Bergamo, IT)
Slides Video

Access the full session

Session thumbnail
Heart failure with preserved ejection fraction

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources